Bioceres Crop Solutions Reports Fiscal First Quarter 2025 Financial and Operational Results
Total revenues in 1Q25 were
1Q25 net loss1 was
Financial & Business Highlights
-
Total revenues in 1Q25 were
$93.3 million , compared to$116.6 million in the same quarter last year. Results were driven by performance inArgentina , where the summer crop season began at an unusually slow pace due to delayed rains and just-in-time purchasing behavior.North America andBrazil gained momentum, despite lingering market headwinds, and partially offset the soft performance inArgentina . -
Operating profit
1
was
$3.4 million and net loss 1 was$5.3 million . Adjusted EBITDA 1 for the quarter was$8.5 million . - RinoTec technology received EPA’s Green Chemistry Challenge Award in the Design of Safer and Degradable Chemicals category.
-
Regulatory approvals for HB4 soybean production were obtained in
Uruguay andBolivia , marking full clearance for the technology across all soybean producing countries in theAmericas .
Management Review
Mr.
This quarter, we saw the benefits of this strategy, with positive contributions from
That said, we remain focused on cost management and a disciplined approach to capital allocation, aiming to both adapt to and increase our flexibility amid current market conditions. At the same time, our commitment to advancing our unique portfolio of technologies is unaltered, encouraged by the recognition and validation our technologies continue to receive from regulators worldwide, as highlighted in this quarter’s report.”
Mr.
Key Financial Metrics
Table 1: 1Q25 Key Financial Metrics |
|||
(In millions of |
1Q24 |
1Q25 |
%CHANGE |
Revenue by Segment |
|
|
|
Crop Protection |
55.9 |
47.7 |
(15%) |
Seed and Integrated Products |
22.3 |
19.8 |
(11%) |
Crop Nutrition |
38.3 |
25.7 |
(33%) |
Total Revenue |
116.6 |
93.3 |
(20%) |
Gross Profit |
45.0 |
37.5 |
(17%) |
Gross Margin |
38.6% |
40.2% |
161 bps |
|
1Q24 |
1Q25 |
%CHANGE |
Net income or loss 1 |
(2.7) |
(5.3) |
(96%) |
Adjusted EBITDA 1 |
16.3 |
8.5 |
(48%) |
1Q25 Summary: Revenues for the quarter totaled
For a full version of Bioceres’ first quarter fiscal year 2025 earnings release, click here .
Fiscal First Quarter 2025 Earnings Conference Call
Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website.
To access the call, please use the following information:
Date:
|
Please dial in 5-10 minutes prior to the start time to register and join. The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here.
A replay of the call will be available through
Toll Free Replay Number: 1-866-813-9403
International Replay Number: Click here
Replay ID: 649318 |
Time:
|
|
US Toll Free dial-in number: 1-833-470-1428 |
|
International dial-in numbers: Click here |
|
Conference ID: 305729 |
|
Webcast: Click here |
About
The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. Through its HB4® program, the company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here.
Forward-Looking Statements
This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company's
1 Please refer to “Use of non-IFRS financial information” for information regarding net loss, operating profit and our use of Adjusted EBITDA and its reconciliation from the most comparable financial measure.
Unaudited Consolidated Statement of Comprehensive Income
(Figures in million of |
|||||
|
Three-month period
|
Three-month period
|
|||
Revenues from contracts with customers |
92.6 |
116.2 |
|||
Initial recognition and changes in the fair value of biological assets at the point of harvest |
0.7 |
0.4 |
|||
Cost of sales |
(55.8) |
(71.6) |
|||
Gross profit |
37.5 |
45.0 |
|||
% Gross profit |
40% |
39% |
|||
Operating expenses |
(34.6) |
(38.5) |
|||
Share of profit of JV |
(0.6) |
1.5 |
|||
Change in net realizable value of agricultural products |
0.6 |
(1.4) |
|||
Other income or expenses, net |
0.5 |
(1.2) |
|||
Operating profit |
3.4 |
5.3 |
|||
Financial result |
(9.8) |
(7.5) |
|||
Profit/(loss) before income tax |
(6.4) |
(2.2) |
|||
Income tax |
1.2 |
(0.4) |
|||
Profit/(loss) for the period |
(5.3) |
(2.7) |
|||
Other comprehensive loss |
0.0 |
(0.9) |
|||
Total comprehensive profit/(loss) |
(5.3) |
(3.6) |
|||
|
|
|
|||
Profit/(loss) for the period attributable to: |
|
|
|||
Equity holders of the parent |
(5.4) |
(4.6) |
|||
Non-controlling interests |
0.2 |
1.9 |
|||
|
(5.3) |
(2.7) |
|||
Total comprehensive profit/(loss) attributable to: |
|
|
|||
Equity holders of the parent |
(5.5) |
(5.4) |
|||
Non-controlling interests |
0.2 |
1.8 |
|||
|
(5.3) |
(3.6) |
Weighted average number of shares |
|
|
Basic |
62.9 |
62.8 |
Diluted |
62.9 |
62.8 |
Unaudited Consolidated Statement of Financial Position
(Figures in million of |
||
ASSETS |
|
|
CURRENT ASSETS |
|
|
Cash and cash equivalents |
32.3 |
44.5 |
Other financial assets |
5.9 |
11.7 |
Trade receivables |
195.4 |
207.3 |
Other receivables |
22.9 |
18.3 |
Recoverable income taxes |
1.0 |
0.7 |
Inventories |
117.7 |
125.9 |
Biological assets |
1.6 |
0.3 |
Total current assets |
376.7 |
408.7 |
NON-CURRENT ASSETS |
|
|
Other financial assets |
0.6 |
0.6 |
Other receivables |
18.5 |
18.0 |
Recoverable income taxes |
0.0 |
0.0 |
Deferred tax assets |
10.7 |
9.7 |
Investments in joint ventures and associates |
40.0 |
39.8 |
Investment properties |
0.6 |
0.6 |
Property, plant and equipment |
74.6 |
74.6 |
Intangible assets |
176.5 |
174.8 |
|
112.2 |
112.3 |
Right of use asset |
17.3 |
11.6 |
Total non-current assets |
450.8 |
442.0 |
Total assets |
827.5 |
850.6 |
LIABILITIES |
|
|
CURRENT LIABILITIES |
|
|
Trade and other payables |
149.9 |
168.7 |
Borrowings |
121.5 |
136.7 |
Employee benefits and social security |
8.3 |
7.3 |
Deferred revenue and advances from customers |
5.7 |
3.9 |
Income tax payable |
3.8 |
4.8 |
Consideration for acquisition |
5.6 |
4.8 |
Lease liabilities |
1.3 |
3.1 |
Total current liabilities |
296.2 |
329.5 |
NON-CURRENT LIABILITIES |
|
|
Borrowings |
46.1 |
42.1 |
Deferred revenue and advances from customers |
1.9 |
1.9 |
Joint ventures and associates |
1.1 |
0.3 |
Deferred tax liabilities |
34.7 |
34.5 |
Provisions |
1.3 |
1.3 |
Consideration for acquisition |
2.2 |
2.5 |
Secured notes |
82.6 |
80.8 |
Lease liabilities |
15.5 |
8.2 |
Total non-current liabilities |
185.4 |
171.6 |
Total liabilities |
481.6 |
501.1 |
EQUITY |
|
|
Equity attributable to owners of the parent |
309.4 |
314.0 |
Non-controlling interests |
36.6 |
35.6 |
Total equity |
345.9 |
349.6 |
Total equity and liabilities |
827.5 |
850.6 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111759157/en/
Paula Savanti
Head of Investor Relations
investorrelations@biocerescrops.com
Source: